Alkermes Q1 Revenues Rise 28.2% to $392.9M as Shares Hit 52-Week High
ALKS•Alkermes posted Q1 revenues of $392.9 million, up 28.2%, and a GAAP net loss of $66.5 million ($0.40 per share) as shares reached a 52-week high near $43.38. Insiders sold 11,034 shares at $33.20–$41.67 under Rule 10b5-1 plans as valuation now exceeds a GF Value of $30.79.
1. Q1 Financial Results
Alkermes posted Q1 revenues of $392.9 million, a 28.2% increase from $306.5 million a year ago, driven by sales of VIVITROL, ARISTADA, LYBALVI and newly acquired LUMRYZ. The company reported a GAAP net loss of $66.5 million, or $0.40 per diluted share, compared with net income of $22.5 million last year.
2. Stock Performance and Valuation
Shares recently traded near $43.38, marking a 52-week high and lifting market capitalization to approximately $7.21 billion. With the stock trading well above a GF Value estimate of $30.79, investors face questions over whether higher revenue growth and sleep medicine expansion justify the elevated valuation.
3. Insider Transactions
On May 4, Executive Vice President and Chief Legal Officer David Joseph Gaffin sold 2,034 shares at $33.20 each, and on June 1, EVP of R&D and Chief Medical Officer Craig C. Hopkinson sold 9,000 shares at a weighted average price of $41.67 under pre-arranged Rule 10b5-1 trading plans.
